{"id":26192,"date":"2026-09-20T07:55:16","date_gmt":"2026-09-20T07:55:16","guid":{"rendered":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/"},"modified":"2026-09-20T09:17:34","modified_gmt":"2026-09-20T09:17:34","slug":"abbvie-pestel-analysis-2026","status":"publish","type":"post","link":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/","title":{"rendered":"AbbVie PESTEL Analysis 2026"},"content":{"rendered":"

AbbVie operates in one of the world\u2019s most regulated and research-intensive industries. Government pricing policy, economic conditions, patient demographics, biotechnology innovation, environmental requirements and intellectual-property law all affect the economics of developing and commercializing medicines.<\/p>\n

For how AbbVie makes money, read our AbbVie Business Model 2026<\/a>.<\/p>\n

Political Factors<\/h2>\n

1. Pharmaceutical pricing policy<\/h3>\n

Government efforts to control medicine spending can affect prices and reimbursement. AbbVie\u2019s large U.S. pharmaceutical portfolio makes changes in federal health policy financially important.<\/p>\n

2. Health-care reimbursement systems<\/h3>\n

Public and private reimbursement frameworks determine patient access and the economics of therapies. Coverage decisions can materially influence adoption even after regulatory approval.<\/p>\n

3. International market access<\/h3>\n

AbbVie operates globally, facing different government approval, pricing and reimbursement systems. Market-access timelines and negotiated prices vary substantially by country.<\/p>\n

4. Trade and supply policy<\/h3>\n

Pharmaceutical manufacturing relies on international supply chains and specialized inputs. Trade restrictions or geopolitical tensions can increase costs or complicate supply continuity.<\/p>\n

5. Government support for biomedical innovation<\/h3>\n

Public research, health systems and regulatory frameworks influence the broader innovation ecosystem. Changes can affect scientific collaboration and the environment for clinical development.<\/p>\n

For AbbVie\u2019s strategic response, see our AbbVie Business Strategy 2026<\/a>.<\/p>\n

Economic Factors<\/h2>\n

1. Health-care spending<\/h3>\n

Demand for medicines is less discretionary than many consumer products, but payer budgets and health-care spending growth influence pricing, access and reimbursement.<\/p>\n

2. Inflation<\/h3>\n

Higher labor, manufacturing and clinical-development costs can raise AbbVie\u2019s expense base. Pharmaceutical pricing may not adjust freely because of payer and regulatory constraints.<\/p>\n

3. Interest rates<\/h3>\n

Financing conditions affect the cost of acquisitions and debt. This matters because external innovation and business development are important parts of AbbVie\u2019s pipeline strategy.<\/p>\n

4. Foreign exchange<\/h3>\n

International sales expose AbbVie to currency movements. Exchange-rate changes can affect reported revenue and earnings even when underlying local-market demand is unchanged.<\/p>\n

5. Capital availability for biotechnology<\/h3>\n

Financing conditions influence the external biotech ecosystem from which AbbVie licenses or acquires assets. Weak capital markets can change valuations and partnership opportunities.<\/p>\n

Social Factors<\/h2>\n

For a consolidated view of AbbVie\u2019s strengths and risks, read our AbbVie SWOT Analysis 2026<\/a>.<\/p>\n

1. Aging populations<\/h3>\n

Older populations can increase prevalence of chronic diseases and demand for effective therapies across immunology, neuroscience, oncology and eye care.<\/p>\n

2. Chronic-disease burden<\/h3>\n

Long-duration diseases create sustained need for therapies that control symptoms or disease progression, supporting large addressable markets for effective medicines.<\/p>\n

3. Patient expectations<\/h3>\n

Patients increasingly expect therapies that improve outcomes and convenience. Dosing frequency, route of administration and quality-of-life benefits can influence treatment adoption.<\/p>\n

4. Mental-health awareness<\/h3>\n

Greater recognition and treatment of psychiatric and neurological conditions can expand demand for neuroscience therapies, an increasingly important AbbVie growth platform.<\/p>\n

5. Consumer demand for aesthetics<\/h3>\n

Aesthetics is influenced by discretionary consumer preferences and physician practices, giving AbbVie exposure to social trends different from reimbursed prescription medicines.<\/p>\n

Technological Factors<\/h2>\n

1. Drug-discovery technologies<\/h3>\n

Advances in biology, chemistry and computational tools can improve target identification and development. AbbVie must continually invest to remain competitive scientifically.<\/p>\n

2. New therapeutic modalities<\/h3>\n

Emerging modalities can create treatments beyond traditional small molecules and antibodies. They also create competition that can disrupt established therapeutic franchises.<\/p>\n

3. Clinical-trial technology<\/h3>\n

Digital tools and data can improve patient recruitment, monitoring and trial execution. Faster, better trials can reduce development time and improve decision quality.<\/p>\n

4. Manufacturing technology<\/h3>\n

Biologic medicines require sophisticated manufacturing and quality systems. Process improvements can increase capacity, consistency and supply resilience.<\/p>\n

5. Cybersecurity and data<\/h3>\n

R&D, clinical and commercial operations depend on sensitive digital information. Cyber incidents can disrupt operations or expose confidential patient and scientific data.<\/p>\n

Environmental Factors<\/h2>\n

1. Pharmaceutical manufacturing footprint<\/h3>\n

Manufacturing facilities use energy, water and materials. Environmental requirements can affect capital investment, operating practices and production costs.<\/p>\n

2. Waste management<\/h3>\n

Pharmaceutical production generates regulated waste streams requiring careful handling and disposal. Compliance failures can create legal and operational consequences.<\/p>\n

3. Supply-chain resilience<\/h3>\n

Extreme weather can disrupt suppliers, transportation and manufacturing. Redundancy and inventory planning are important for medicines that patients require continuously.<\/p>\n

4. Energy and emissions<\/h3>\n

Energy efficiency and sourcing influence operating costs and environmental performance across laboratories, offices and manufacturing sites.<\/p>\n

5. Climate-related physical risks<\/h3>\n

Long-lived facilities can face storms, heat, flooding and other physical risks. Site resilience can affect continuity of pharmaceutical supply.<\/p>\n

Legal Factors<\/h2>\n

1. Patent and exclusivity law<\/h3>\n

AbbVie\u2019s economics depend heavily on patents and regulatory exclusivity. Expiration or successful challenges can trigger generic or biosimilar competition and rapid revenue erosion.<\/p>\n

2. Drug approval regulation<\/h3>\n

Medicines must satisfy extensive safety and efficacy requirements before approval. Regulators can also require post-marketing studies or change labels after launch.<\/p>\n

3. Product liability<\/h3>\n

Unexpected safety issues can generate litigation and financial liabilities in addition to regulatory consequences. Large patient populations can magnify exposure.<\/p>\n

4. Marketing and promotion rules<\/h3>\n

Pharmaceutical promotion is tightly regulated. AbbVie must ensure commercial communications and interactions with health-care professionals comply with applicable laws.<\/p>\n

5. Competition and transaction review<\/h3>\n

Acquisitions and collaborations can face antitrust or other regulatory review. Because external innovation is strategically important, transaction regulation can influence pipeline-building options.<\/p>\n

These PESTEL forces interact strongly in pharmaceuticals. Scientific innovation determines what treatments are possible, regulators decide whether they can reach patients, payers influence economic access and patent law determines how long innovators can earn protected returns. AbbVie\u2019s business model therefore depends on the entire institutional ecosystem around medicine development.<\/p>\n

U.S. policy is particularly consequential because the country contributes a large share of revenue for major products. Changes in drug-price negotiation, reimbursement or patient access can influence the economics of products even when clinical demand remains unchanged.<\/p>\n

Internationally, health systems often negotiate prices differently from the United States. This can produce lower realized prices but broaden patient access. AbbVie must decide where and when to launch based on regulatory approval, reimbursement and commercial opportunity in each market.<\/p>\n

Economic conditions also influence biotechnology dealmaking. When external financing is scarce, smaller biotechnology companies may seek partnerships or acquisitions, potentially creating opportunities for well-capitalized firms. Strong markets can increase competition and valuations for the same assets.<\/p>\n

Demographics support long-term demand but do not guarantee product success. Aging populations can increase disease prevalence, yet therapies still need differentiation and reimbursement. AbbVie\u2019s opportunity lies in targeting conditions where better outcomes create enough value to support adoption.<\/p>\n

Social expectations around treatment convenience are increasingly important. Oral therapies, less frequent dosing or easier administration can influence patient and physician preferences when efficacy is comparable. Product design therefore affects commercial competitiveness alongside clinical endpoints.<\/p>\n

Technology can improve the probability and speed of development, but it does not remove biological uncertainty. AI and computational tools may help identify targets or molecules, while clinical trials remain necessary to establish safety and efficacy in patients.<\/p>\n

Manufacturing technology matters after approval as much as discovery technology matters before it. Scaling biologics reliably requires process control, quality assurance and regulatory compliance. Improvements can increase capacity and lower unit costs, while failures can interrupt supply.<\/p>\n

Environmental and climate factors can become health-system issues as well as operating issues. Extreme weather can disrupt manufacturing, logistics and clinical sites. Global supply networks therefore need resilience rather than optimization solely for lowest cost.<\/p>\n

Patent litigation is a recurring legal feature of the business. Competitors may challenge intellectual-property rights before stated expiry dates, creating uncertainty around the effective period of exclusivity. AbbVie must defend patents while preparing commercially for eventual competition.<\/p>\n

Acquisition regulation also matters because external innovation is a core strategic tool. Greater scrutiny of pharmaceutical transactions could alter which assets AbbVie can acquire, transaction timelines or deal structures, increasing the importance of partnerships and internal R&D as alternative routes.<\/p>\n

For 2026, the most important external balance is between rapid biomedical innovation and increasing pressure on drug economics. AbbVie can benefit from new science and unmet medical need, but it must demonstrate clinical value strongly enough to secure regulatory approval, reimbursement and durable adoption.<\/p>\n

Economic conditions can also affect aesthetics differently from prescription pharmaceuticals. Botox Cosmetic and related products are more discretionary, so consumer confidence and disposable income can influence demand even when AbbVie\u2019s reimbursed therapeutic portfolio remains relatively resilient.<\/p>\n

Interest rates matter through AbbVie\u2019s balance sheet and transaction strategy. Acquisitions can require substantial financing, and higher borrowing costs raise the hurdle rate for external innovation. This increases the importance of disciplined valuation when bidding for biotechnology assets.<\/p>\n

Patient demographics interact with therapeutic innovation. An aging population may increase the number of patients with neurological, oncological and ophthalmic conditions, but treatment markets can also expand when better diagnostics identify patients earlier or more accurately.<\/p>\n

Social awareness can reshape treatment rates. Greater discussion of migraine and mental health, for example, can encourage diagnosis and treatment seeking. AbbVie\u2019s neuroscience portfolio can benefit if more eligible patients enter care, provided its therapies remain clinically competitive.<\/p>\n

Data science can improve portfolio decisions as well as drug discovery. AbbVie can use clinical and real-world evidence to identify subpopulations, monitor outcomes and prioritize indications. The strategic value comes from making better development decisions, not merely adopting new technology.<\/p>\n

Cybersecurity is especially important because clinical development involves sensitive patient data and proprietary scientific information. A breach can create privacy liability while also exposing valuable intellectual property or interrupting regulated processes.<\/p>\n

Supply-chain environmental resilience has direct patient consequences. Medicines cannot simply be delayed indefinitely after a disruption. AbbVie needs contingency planning for critical materials, manufacturing capacity and logistics to maintain continuity of supply.<\/p>\n

Legal protection extends beyond patents to regulatory exclusivity, trademarks and confidential know-how. Different forms of protection can overlap, but none eliminates eventual competition. Lifecycle planning must therefore assume that mature products will ultimately face erosion.<\/p>\n

Product liability and safety regulation can also interact. New adverse-event information may lead to regulatory action and litigation simultaneously. Strong pharmacovigilance systems are therefore both a compliance requirement and a form of financial risk management.<\/p>\n

Source:<\/strong> AbbVie Inc., 2025 Annual Report \/ Form 10-K<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.<\/p>\n","protected":false},"author":3,"featured_media":26247,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_focuskw":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[156],"tags":[],"class_list":{"0":"post-26192","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-pestel-analysis"},"yoast_head":"\nAbbVie PESTEL Analysis 2026 - The Strategy Story<\/title>\n<meta name=\"description\" content=\"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie PESTEL Analysis 2026 - The Strategy Story\" \/>\n<meta property=\"og:description\" content=\"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"The Strategy Story\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-20T07:55:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T09:17:34+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/09\/national-cancer-institute-KMvoHcB-w5g-unsplash-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Shikhar Goel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shikhar Goel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/\",\"url\":\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/\",\"name\":\"AbbVie PESTEL Analysis 2026 - The Strategy Story\",\"isPartOf\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\"},\"datePublished\":\"2026-09-20T07:55:16+00:00\",\"dateModified\":\"2026-09-20T09:17:34+00:00\",\"author\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/8eed62769b0125006923a7fdc33f1071\"},\"description\":\"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.\",\"breadcrumb\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thestrategystory.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie PESTEL Analysis 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\",\"url\":\"https:\/\/thestrategystory.com\/blog\/\",\"name\":\"The Strategy Story\",\"description\":\"Simplifying Business Strategies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/8eed62769b0125006923a7fdc33f1071\",\"name\":\"Shikhar Goel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8b6c6c1213b8835c1731c5d95c1ea3103684847f09cc6d1aab64d3e432f66481?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8b6c6c1213b8835c1731c5d95c1ea3103684847f09cc6d1aab64d3e432f66481?s=96&d=mm&r=g\",\"caption\":\"Shikhar Goel\"},\"url\":\"https:\/\/thestrategystory.com\/blog\/author\/tss-publisher\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie PESTEL Analysis 2026 - The Strategy Story","description":"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie PESTEL Analysis 2026 - The Strategy Story","og_description":"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.","og_url":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/","og_site_name":"The Strategy Story","article_published_time":"2026-09-20T07:55:16+00:00","article_modified_time":"2026-09-20T09:17:34+00:00","og_image":[{"width":640,"height":465,"url":"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/09\/national-cancer-institute-KMvoHcB-w5g-unsplash-1.jpg","type":"image\/jpeg"}],"author":"Shikhar Goel","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Shikhar Goel","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/","url":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/","name":"AbbVie PESTEL Analysis 2026 - The Strategy Story","isPartOf":{"@id":"https:\/\/thestrategystory.com\/blog\/#website"},"datePublished":"2026-09-20T07:55:16+00:00","dateModified":"2026-09-20T09:17:34+00:00","author":{"@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/8eed62769b0125006923a7fdc33f1071"},"description":"AbbVie PESTEL analysis 2026 examines the political, economic, social, technological, environmental and legal factors affecting the company based on its 2025 Annual Report and Form 10-K.","breadcrumb":{"@id":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thestrategystory.com\/blog\/abbvie-pestel-analysis-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thestrategystory.com\/blog\/"},{"@type":"ListItem","position":2,"name":"AbbVie PESTEL Analysis 2026"}]},{"@type":"WebSite","@id":"https:\/\/thestrategystory.com\/blog\/#website","url":"https:\/\/thestrategystory.com\/blog\/","name":"The Strategy Story","description":"Simplifying Business Strategies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/8eed62769b0125006923a7fdc33f1071","name":"Shikhar Goel","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8b6c6c1213b8835c1731c5d95c1ea3103684847f09cc6d1aab64d3e432f66481?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8b6c6c1213b8835c1731c5d95c1ea3103684847f09cc6d1aab64d3e432f66481?s=96&d=mm&r=g","caption":"Shikhar Goel"},"url":"https:\/\/thestrategystory.com\/blog\/author\/tss-publisher\/"}]}},"_links":{"self":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/26192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/comments?post=26192"}],"version-history":[{"count":2,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/26192\/revisions"}],"predecessor-version":[{"id":26199,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/26192\/revisions\/26199"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media\/26247"}],"wp:attachment":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media?parent=26192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/categories?post=26192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/tags?post=26192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}